Symtuza generic
Symtuza is an antiretroviral drug owned by Janssen Prods. The active ingredients in Symtuza are Cobicistat, Darunavir, Emtricitabine, Tenofovir Alafenamide Fumarate. The drug was first approved for market use on 17 July, 2018 and is available in tablet form for oral administration.
When will Symtuza generic be available?
Symtuza has a total of 9 patents, with one already expired (US7803788). The generic version of Symtuza is expected to be released after 19 July, 2038, following the expiration of the last patent (US10786518).
Symtuza uses
Symtuza is used for the treatment of HIV-1 infection in adults and pediatric patients who weigh at least 40kg. This suitable for those with no prior antiretroviral treatment history or those already virologically suppressed on a stable antiretroviral regimen for at least six months. Its active ingredients work in synergy to inhibit the monooxygenase activity of the enzyme cytochrome P450, which is a crucial component in the life cycle of HIV.
Symtuza patent expiration
Symtuza holds nine patents related to its formulation and use, with the latest one, US10786518, set to expire on 19 July, 2038. This represents the earliest possible date for the release of a generic version of Symtuza. The details of the patents are provided below: